Exchange: NASDAQ·Updated 12:55 PM EDT
XERS logo

XERS Xeris Biopharma Holdings Inc

$8.63
$0.045
(0.52%)
Today
Reported EarningsAug 6
Mkt Cap$1.56B
Vol389,470.00

About XERS

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
30

Bearish Sentiment

How do you feel about XERS?

Advertisement|Remove ads.